Profitelligence Profitelligence · Filing Ledger Open IQV research →

Form 8-K · Current Report · Filed 2025-09-02

IQVIA Announces Planned CFO Transition in Early 2026

IQVIA Holdings Inc. announced on September 2, 2025, the planned transition of its Chief Financial Officer (CFO) role. Michael J. Fedock will succeed Ronald E. Bruehlman as Executive Vice President and Chief Financial Officer effective February 28, 2026. This transition is part of the company's previously announced CFO succession plan. Mr. Bruehlman will retire and transition to the role of Senior Advisor to the CEO. The appointment and transition were announced via press release under Regulation FD.

Filer
Iqvia Holdings Inc. IQV · NYSE
Filed
Accession
0001193125-25-193510
CIK
0001478242
Signal
High impactHealthcare

Items reported

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

New CFO Appointed
Item 7.01

Regulation FD Disclosure

Regulation FD Disclosure

Market reaction

Close before filing

$190.81

Next session

-3.2%

Since filing

+23.2%

Latest close

$235.02

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from IQV reporting the same item, with the next session's move:

About Iqvia Holdings Inc.

Iqvia Holdings Inc. is a leading global provider of advanced analytics, technology solutions, and contract research services. Its primary function is to support the healthcare sector by offering data-driven insights and innovations that underpin strategic decision-making across pharmaceutical, biotechnology, and medical device industries. Iqvia plays a crucial role in facilitating drug development through its comprehensive clinical research capabilities, encompassing everything from clinical trials to regulatory submissions. Additionally, its technology solutions leverage artificial intelligence and machine learning to optimize clinical and commercial operations, contributing to enhanced patient outcomes and streamlined healthcare delivery. Iqvia's integrated services impact sectors such as drug safety, patient engagement, and real-world evidence, making it an indispensable partner for healthcare companies seeking to navigate complex markets and regulatory environments. Globally recognized for its vast data repository and cutting-edge analytical platforms, Iqvia serves as a pivotal player in the transformation of the healthcare landscape, empowering organizations to accelerate innovation and improve patient care.

Exchange NYSE Industry Diagnostics & Research Company website ↗

Never miss another IQV filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts